



# Grant of Options and PDMR Dealing

March 22, 2023 7:00 AM EDT

RNS Number : 7652T  
MaxCyte, Inc.  
22 March 2023



## MaxCyte, Inc.

("MaxCyte" or the "Company")

### Grant of Options and PDMR Dealing

**Gaithersburg, Maryland - 22 March 2023:** MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on 20 March 2023, a total of 480,000 options of common stock in the Company ("Common Stock") were granted to PDMRs of the Company ("Option Grants"). Details of the Option Grants are given below:

Option Grants to PDMRs	
Doug Doerfler	400,000
Rekha Hemrajani	40,000
Yasir Al-Wakeel	40,000
<b>Total</b>	<b>480,000</b>

Options granted to Doug Doerfler vest 12/48<sup>th</sup> of the total grant one year after date of grant, and thereafter vest 1/48<sup>th</sup> per month for 36 months after the date of grant.

Of the option granted to Rekha Hemrajani and Yasir Al-Wakeel, Non-Executive Directors of the Company, 23,333 of the Option Grants vested on the date of the grant, and the remaining 16,667 shares will vest in 15 equal monthly installments thereafter, beginning on April 14, 2023.

The Option Grants have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 20 March 2023, being \$4.19.

#### About MaxCyte

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation<sup>®</sup> technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT<sup>™</sup> platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx<sup>®</sup>, STx<sup>®</sup>, GTx<sup>®</sup> and VLx<sup>™</sup>; a portfolio of proprietary

related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Learn more at [maxcyte.com](http://maxcyte.com) and follow us on [Twitter](https://twitter.com/maxcyte) and [LinkedIn](https://www.linkedin.com/company/maxcyte).

**MaxCyte Contacts:**

**US IR Adviser**

**Gilmartin Group**

David Deuchler, CFA

+1 415-937-5400

[ir@maxcyte.com](mailto:ir@maxcyte.com)

**Nominated Adviser and Joint**

**Corporate Broker**

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

**UK IR Adviser**

**Consilium Strategic**

**Communications**

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

[maxcyte@consilium-comms.com](mailto:maxcyte@consilium-comms.com)

**About MaxCyte**

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at [maxcyte.com](http://maxcyte.com) and follow us on [Twitter](https://twitter.com/maxcyte) and [LinkedIn](https://www.linkedin.com/company/maxcyte).

**NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	a) Doug Doerfler b) Rekha Hemrajani c) Yasir Al-Wakeel
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/status	a) President and CEO b) Non-Executive Director c) Non-Executive Director
b)	Initial notification /Amendment	Initial notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	MaxCyte Inc.
b)	LEI	54930053YHXULRFCU991

4	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>									
a)	Description of the financial instrument, type of instrument  Identification code	Common Stock of \$0.01 each  US57777K1060								
b)	Nature of the transaction	Grant of options of common stock								
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Exercise Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>a) \$4.19</td> <td>400,000</td> </tr> <tr> <td>b) \$4.19</td> <td>40,000</td> </tr> <tr> <td>c) \$4.19</td> <td>40,000</td> </tr> </tbody> </table>	Exercise Price(s)	Volume(s)	a) \$4.19	400,000	b) \$4.19	40,000	c) \$4.19	40,000
Exercise Price(s)	Volume(s)									
a) \$4.19	400,000									
b) \$4.19	40,000									
c) \$4.19	40,000									
d)	Aggregated information  - Aggregated volume  - Price	480,000  \$4.19								
e)	Date of the transaction	March 20, 2023								
f)	Place of the transaction	USStock Exchange, Nasdaq								

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBRGDXXGDDGXB